79 results on '"Renneville, Aline"'
Search Results
2. Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations
3. Comprehensive mutational profiling of core binding factor acute myeloid leukemia
4. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
5. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
6. Disease evolution and outcomes in familial AML with germline CEBPA mutations
7. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
8. MYD88 L265P mutation in Waldenstrom macroglobulinemia
9. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
10. Clonal architecture of chronic myelomonocytic leukemias
11. Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
12. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
13. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
14. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study
15. 1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
16. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations
17. SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL
18. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations
19. Clonal Hematopoiesis in Erdheim-Chester Disease
20. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production
21. Granulomonocytic Progenitors (GMPs) Are Key Target Cells of Azacitidine in MDS and AML
22. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients
23. Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation
24. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
25. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder
26. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
27. TP53 Mutation in Waldenstrom Macroglobulinemia
28. De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory
29. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases
30. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM
31. A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM
32. NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group
33. Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group
34. Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS)
35. Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS)
36. Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia
37. Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group
38. Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group
39. NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience
40. Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)
41. Final Analysis of the ALFA 0701 Study
42. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
43. The B7-H3 Protein In Acute Myeloid Leukemia
44. Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA
45. Heterogeneity Of Patients With Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Nucleophosmin-1 (NPM1) Gene Mutation: An Acute Leukemia French Association (ALFA) Study
46. Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing
47. Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM
48. Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML)
49. Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.
50. Effector CD4+CD45RA−CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.